Introduction
Sarcopenia, the age-related decline in muscle mass and muscle strength, is a major driver of reduced physical function in old age [1] . Sarcopenia is a risk factor for falls, hospitalisation and the need for institutional care. Finding ways to ameliorate or even reverse sarcopenia should therefore be a key research aim [2] .
The pathophysiology of sarcopenia is not well understood, but is likely to result from disruption to multiple physiological systems [3] . Candidate mechanisms include oxidative stress, mitochondrial dysfunction, chronic inflammation and the effect of proinflammatory cytokines, low circulating levels of hormones (e.g. insulin-like growth factor-1, testosterone) needed to maintain muscle mass, and reduced regenerative capacity of muscle due to low levels of muscle precursor 'satellite' cells.
Vascular disease is common in older people, and reduced blood supply to skeletal muscle, either via inadequate cardiac output or via peripheral micro-or macrovascular disease, may contribute to sarcopenia [4] [5] [6] . It is therefore possible that interventions that improve vascular health might be able to improve skeletal muscle function in sarcopenia. Of particular interest are the effects of renin-angiotensin-aldosterone system (RAAS) blocking drugs. Angiotensin converting enzyme (ACE) inhibitors have been shown to improve exercise capacity in older, functionally impaired patients [7] and patients with peripheral vascular disease [8] , but showed no effect in healthy older people [9] . Observational data also show a slower reduction in walking speed in patients treated for hypertension using ACE inhibitors [10] , and the known deleterious effects of angiotensin-2 on muscle function in non-human models lend biological plausibility to these findings [11] .
Previous studies have focussed on the effects of ACE inhibitors on endurance exercise capacity [7, 10, 12] . The hallmark of sarcopenia is a preferential loss of type 2 (fast-twitch) muscle fibres [13] , which play a major role in development of maximal muscle strength, in contrast to the role that type 1 fibres play in endurance muscle function. Grip strength, as a measure of maximal muscle strength, therefore may better reflect the pathophysiological changes seen in sarcopenia. Previous studies have examined the cross-sectional association between cardiovascular medication use and grip strength or mobility limitation [14] [15] [16] , but such studies are highly prone to confounding. More robust, longitudinal analyses are desirable, and we therefore examined the association between ACE inhibitor treatment and grip strength using data from the Hertfordshire Cohort Study (HCS), and compared this association with that for thiazide diuretics-known to activate the RAAS, and statins, known to have beneficial vascular effects not mediated by the RAAS.
Methods
We analysed data collected for the HCS. The cohort has been described previously in detail [17] . A total of 3822 men and 3284 women born in Hertfordshire, England in 1931-1939 and still resident in the county were traced via the NHS central registry in 1998. Of which, 3126 men and 2973 women were contacted after obtaining permission from their general practitioners; between 1998 and 2004, a total of 1684 men and 1541 women participated in a nurse-administered home interview.
Data collected at the baseline interview included medical history of hypertension, diabetes, angina diagnosed using the Rose Angina questionnaire [18] , an history of coronary artery bypass grafting or percutaneous coronary angioplasty. All current medications were recorded and coded according to British National Formulary categories. A clinic visit was conducted as part of the baseline data collection on 1579 men and 1418 women. Height and weight were recorded, along with grip strength (maximum of three measures on each hand using a Jamar handgrip dynamometer). Blood pressure was measured using a Dinamap model 8101 (GE Medical Systems, Slough, UK); the mean of three measures was calculated. A 12 lead ECG was performed and coded to the Minnesota protocol [19] . Four hundred and ninety-eight men and 468 women resident in East Hertfordshire also underwent dual energy X-ray absorptiometry (DXA) scanning at the lumbar spine and femoral neck; this group of 966 participants were followed up as described below. The study conformed to the principles of the Declaration of Helsinki; data collection for the HCS were approved by the Hertfordshire research ethics committee (references EC98248, WHO2/98, 04/Q0201/2 and 05/ Q0201/40). All participants gave written informed consent.
A second wave of data collection was undertaken in 2004-2005; a mean of 4.4 years later [20] . Of the 498 men and 468 women from East Hertfordshire who had undergone the HCS baseline evaluation including DXA scan, eight had died, six had moved away, we were unable to obtain GP permission to approach four people, 47 were no longer on family doctor lists and 17 were unavailable. Hence, 437 men and 447 women were invited to take part in the Musculoskeletal follow-up (MSFU) study. Of these, 322 men (74%) and 320 women (72%) agreed to attend this follow-up clinic. Medical history, blood pressure, grip strength and medication use were collected as before.
Statistical analyses
Descriptive statistics were generated for baseline age, sex, grip and medication use. All analyses are shown separately for men and women due to significant differences in grip strength between sexes. A two-sided P value of <0.05 was taken as significant for all analyses. Analyses were performed using PASW v18 (IBM, New York, USA). Baseline mean grip strength was calculated for users and non-users in each medication group (ACE inhibitor use, statin use and thiazide use). Means (and 95% confidence intervals (CI)) for annualised changes in grip strength (in kg per year) between baseline and follow-up were calculated for each combination of medication use (i.e. no use at baseline or follow-up, use at baseline but not at follow-up; no use at baseline, but use at follow-up; and use at both baseline and follow-up) and differences in change in grip strength between medication usage groups were analysed using ANOVA. Positive values denote an increase in grip strength over time.
Linear regression modelling (using ANCOVA) was used to analyse differences in change in grip strength for each combination of medication use at baseline and follow-up after adjustment for baseline age, grip strength, height and weight, baseline hypertensive status (defined as BP > 160/100 or use of any antihypertensive) and presence of ischaemic heart disease (positive Rose angina questionnaire, Q waves on ECG, previous coronary revascularisation procedure). The referent group for all analyses was individuals not using the medication under study at baseline or at follow-up. For ACE inhibitor analyses, patients taking angiotensin receptor blockers (either at baseline or, for change in grip, at follow-up) were excluded. Binary logistic regression analysis was conducted to test baseline predictors of dropout, with the aim of testing whether taking each medication at baseline was independently associated with dropout during follow-up. A stepwise, forward conditional model was used, with P < 0.1 to enter the model.
Results
Data on 639 men and women who had grip strength measured at HCS baseline and MSFU clinics were available for analysis. Baseline data are described in Table 1 . Analysis of baseline grip strength is presented separately for males and females in Table 2 . No significant differences in grip strength were evident at baseline comparing those taking or not taking each medication group. Baseline users of ACE inhibitors were not significantly older than non-users (65.5 versus 64.9 years, P = 0.14), but did have higher baseline systolic blood pressure (140 versus 134 mmHg, P = 0.02), diastolic blood pressure (74 versus 71 mmHg, P = 0.03) and body mass index (BMI) (28.0 versus 26.7 kg m −2 , P = 0.05). Thiazide users at baseline were slightly older than non-users (66.0 versus 64.9 years, P = 0.001), and had higher systolic blood pressure (140 versus 134 mmHg, P = 0.007) and BMI (28.6 versus 26.6 kg m −2 , P = 0.001). Statin users were again slightly older, but had similar baseline blood pressure and BMI to non-users at baseline. Table 3 shows changes in grip strength (with 95% CI) over time according to different patterns of exposure to each medication group. Reductions in grip strength were in the order of 1% per year for men and 3% per year for women. No significant differences in the rate of change of grip strength were identified when different patterns of medication exposure were contrasted, without or with adjustment for baseline variables, and point estimates of decline in grip strength were similar across medication use groups.
We tested for evidence of participation bias owing to differential dropout rates between different medication groups. However, baseline use of each medication class was similar in those who attended follow-up and in those who did not attend follow-up (Table 4) . Binary logistic regression, including medication use at baseline, age, sex, baseline grip, height, weight, hypertension and ischaemic heart disease showed that only sex, weight and height remained as predictors of participation in follow-up (P < 0.1); ACE inhibitor use, statin use and thiazide use were not associated with follow-up status.
Discussion
ACE inhibitors, thiazides and statins do not appear to be associated with change in grip strength over a 4-year followup period among the community dwelling older men and women who participated in the HCS. The aetiology of sarcopenia is incompletely understood, but cross-sectional studies have suggested a correlation between indices of vascular health and lower limb muscle mass and function [5, 6] . Angiotensin-2 is known to have effects on muscle function [11] ; polymorphisms of the ACE genotype have been found to predict response to training in army recruits [21] and appear to influence elite athletic ability [22] . In older people, continuous ACE inhibitor use is associated with a slower reduction in walking speed over time when compared with other antihypertensive use [10] , and a randomised controlled trial of ACE inhibitors versus placebo showed significant improvements in walking distance and quality of life in the ACE inhibitor group [7] . ACEi, angiotensin converting enzyme inhibitor. Adjusted to mean baseline age, height, weight, baseline grip strength, and to reference category (absence of disease) for ischaemic heart disease and hypertension.
Grip strength relies on type 2 muscle fibre function to generate maximal force, and it is type 2 fibre loss that is thought to dominate in the pathophysiology of sarcopenia. Previous observational work has not found an association between cross-sectional ACE inhibitor use and either selfreported mobility limitation [14] , self-reported indices of frailty [15] or measured grip strength [16] . Despite the lack of association seen in previous cross-sectional studies, including from this cohort [16] , it is important to test such associations in longitudinal studies-cross-sectional studies are prone to selection bias which could obscure a genuine association, and longitudinal studies thus provide a more robust test of the hypothesis, with their lower risk of selection bias and ability to test for reverse causality. No association was seen between ACE inhibitor use and decline in grip strength in a group of patients with heart failure or hypertension [23] . Outcomes in intervention studies that rely on type 2 muscle fibre function (grip strength, sit to stand test, short physical performance battery) have also not shown improvement with ACE inhibitor use [7, 9] . The results from the current study are therefore consistent with much of the existing literature; patients taking ACE inhibitors did not improve or preserve their grip strength more than those not taking ACE inhibitors, and thiazides (which activate the renin-angiotensin system) showed no effect in accelerating the rate of decline in grip strength. Statins, which have no effect on the reninangiotensin system, but which have been associated with improved outcomes after rehabilitation [24] also showed no effect, and this is again consistent with the lack of effect seen on mobility in population-based observational studies [14] . All three agents are known to exert beneficial effects on vascular health, yet none of the agents were associated with slower decline in grip strength than those not taking these agents; these results do not support a general association between agents that improve vascular health and rate of decline in grip strength.
Strengths of our study are the extensive characterisation, including medication data, of the HCS participants, and the consistent measurement of grip strength according to strict protocol by trained research nurses who completed interand intra-observer variation studies throughout the HCS fieldwork. However, the HCS participants are a relatively healthy group of young-old community dwelling individuals; it is not therefore possible to exclude an effect of ACE inhibitor use in a frailer population who may have established sarcopenia or other myopathy. The proportion of participants with established vascular disease at baseline was small, and thus we were unable to perform subgroup analysis to test whether this group might show an association between ACE inhibitor use and slower decline in grip strength. This issue can be resolved only by testing these associations in a group with more prevalent vascular disease at baseline. The relatively small number of participants taking the medications under study limits our ability to exclude the presence of an effect, although comparing the point estimates across groups does not suggest that large effects are evident. There is however a tradeoff between sample size and detail of phenotypic characterisation. Much larger samples, enriched for vascular disease, would certainly give more accurate estimates of any effect size, but providing sufficient characterisation (e.g. grip strength over a long enough follow-up) in such a sample size is a significant undertaking. Future cohorts or syndicates of existing cohorts may be able to provide data on this scale. Finally, although the follow-up time in this cohort was only 4.4 years, we saw no signal to suggest that longer follow-up time would have produced significant associations between patterns of use of ACE inhibitors, thiazides and statins and change in grip strength. Future studies need to specifically test whether any beneficial effect of ACE inhibitors is confined to patients with poor endurance, as opposed to poor maximal muscle strength. Such studies would be augmented by use of muscle biopsy to elucidate any mechanism of action at the level of the muscle fibre; future studies will need to enrol patients with predefined endurance limitation as well as patients with established sarcopenia according to current consensus definitions.
Key points
• Observational and intervention studies have suggested that ACE inhibitors may improve walking speed in older people without heart failure.
• Data examining the effect of cardiovascular medications on grip strength are sparse.
• ACE inhibitors, thiazides and statins were not associated with slower decline in grip strength in this study.
• This study examined a healthy cohort; future work should focus on frailer patients with more extensive vascular disease.
